AstraZeneca Faces Scrutiny Over Operations Expansion in Russia Amid Ukraine Conflict

AstraZeneca, Britain’s largest pharmaceuticals company, has come under intense criticism after reports revealed the expansion of its operations in Russia, despite the ongoing war in Ukraine. Financial filings and investigative research have laid bare the increase in the company’s sales, taxes, and workforce within Russia, raising questions about its commitment to neutrality.

According to accounts filed in Moscow, AstraZeneca’s sales in Russia surged by 30 per cent over the past year, reaching £838.8 million, while its taxable income rose to £21.5 million. The company’s workforce in Russia also expanded, with the number of employees increasing from 1,599 in 2022 to 1,901 by the end of 2024. These figures were disclosed amidst revelations that AstraZeneca continues to sponsor Kremlin-linked business events.

Evidence uncovered by The Times showed that the company’s Russia chief executive, Panarina Irina Viktorovna, spoke at a high-profile conference in April alongside sanctioned Russian officials. The event, sponsored by AstraZeneca, focused on strategies to rebuild trust between Europe and Russia. Participants included Russia’s deputy minister of foreign affairs and other Kremlin-aligned figures, sparking outrage in the UK political and business communities.

The company’s defence hinges on its responsibility to deliver life-saving medicines to patients worldwide, including the seven million patients in Russia who rely on AstraZeneca’s products. Pascal Soriot, the group’s chief executive, has repeatedly emphasised that medicines and vaccines are excluded from sanctions due to their essential nature. However, critics argue that this justification cannot excuse the apparent expansion and economic reinforcement of Russia at a time when the UK government remains one of Ukraine’s strongest allies.

Dame Emily Thornberry, chair of the Foreign Affairs Committee, described the situation as deeply disappointing, stating that companies should not treat their operations in Russia as business as usual. Concerns have also been raised by Andrii Onopriienko, leader of the Leave Russia project at the Kyiv School of Economics, who criticised AstraZeneca for engaging with Kremlin-aligned organisations while claiming political neutrality.

The controversy surrounding AstraZeneca has reignited the broader debate over corporate responsibility during geopolitical conflicts. While many Western companies have exited the Russian market in light of sanctions and ethical considerations, AstraZeneca’s actions highlight the challenges faced by multinational corporations in balancing political neutrality and moral accountability.